Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial - Ferrari, MD; Diener, HC; Ning, X (Lancet, 2019)